Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
HER2 classification relies on immunohistochemistry ... HER2 assays are semiquantitative and were optimized to detect HER2 overexpression. Furthermore, some data suggest that IHC 0 cancers respond ...
Competitive Intelligence In Breast Cancer: Tracking The Evolving HR+ HER2-Ve Breast Cancer Landscape
A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor ...
And as trials testing Herceptin at earlier stages and in combination with other drugs continue, experts are starting to wonder what besides HER2 overexpression might be influencing an individual's ...
HER2 overexpression is a hallmark of several tumors, including those originating from breast, stomach, bladder, and colon. Patients relapse or become unresponsive to antibody-based regimens ...
Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...
“From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for ...
Exclusion criteria were the following: non-overexpression of HER2 receptor; cerebral or meningeal metastasis; grade > 1 peripheral neuropathy according to NCI-CTC; severe cardiac dysfunction or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results